Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506424 | 0.93 | HDAC6 (0.63) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4502148 | 0.89 | GSK3B (0.65) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4491185 | 0.88 | GSK3B (0.64) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4499827 | 0.87 | GSK3B (0.64) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4494630 | 0.87 | HDAC1 (0.58) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4484182 | 0.86 | HDAC1 (0.57) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4486772 | 0.85 | HDAC1 (0.66) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4491275 | 0.84 | GSK3B (0.68) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4484179 | 0.84 | GSK3B (0.59) | GSK3BHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4493825 | 0.84 | GSK3B (0.78) | GSK3BHDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | claimed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | claimed |
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GSK3B 1726/4885HDAC1 1370/4885HDAC2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.